ArticleInternational journal of hematology2012
Erythropoietin stimulation decreases hepcidin expression through hematopoietic activity on bone marrow cells in mice.
Article in International journal of hematology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 49 citations in OpenAlex.
- Four-Week Studies of Oral Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor GSK1278863 for Treatment of Anemia.Journal of the American Society of Nephrology : JASN · 2016Trial
- Outline of Iron Metabolism, with Emphasis on Erythroid Cells.Mediterranean journal of hematology and infectious diseases · 2025Review
- Conventional and complementary alternative medicine therapies for renal anemia: a literature review.Frontiers in endocrinology · 2024Review
- Iron Mining for Erythropoiesis.International journal of molecular sciences · 2022Review
- Direct modulation of hepatocyte hepcidin signaling by iron.World journal of hepatology · 2021Article
- Erythroferrone and hepcidin as mediators between erythropoiesis and iron metabolism during allogeneic hematopoietic stem cell transplant.American journal of hematology · 2021Article
- Daprodustat for anemia: a 24-week, open-label, randomized controlled trial in participants with chronic kidney disease.Clinical kidney journal · 2019Article
- Osteopontin deletion drives hematopoietic stem cell mobilization to the liver and increases hepatic iron contributing to alcoholic liver disease.Hepatology communications · 2018Article
- The effect of frequency of C.E.R.A. administration on the contribution of dietary iron for erythropoiesis.International journal of hematology · 2017Article
- Daily propranolol administration reduces persistent injury-associated anemia after severe trauma and chronic stress.The journal of trauma and acute care surgery · 2017Article
- Regulation of the Iron Homeostatic Hormone Hepcidin.Advances in nutrition (Bethesda, Md.) · 2017Review
- Characterization of erythropoietin and hepcidin in the regulation of persistent injury-associated anemia.The journal of trauma and acute care surgery · 2016Article
- Efficacy estimation of erythropoiesis-stimulating agents using erythropoietin-deficient anemic mice.Haematologica · 2016Article
- Article
- Article
- Reduction of a marker of oxidative stress with enhancement of iron utilization by erythropoiesis activation following epoetin beta pegol administration in iron-loaded db/db mice.International journal of hematology · 2016Article
- Roles of renal erythropoietin-producing (REP) cells in the maintenance of systemic oxygen homeostasis.Pflugers Archiv : European journal of physiology · 2016Review
- Epoetin beta pegol alleviates oxidative stress and exacerbation of renal damage from iron deposition, thereby delaying CKD progression in progressive glomerulonephritis rats.Physiological reports · 2015Article
- Hepcidin: regulation of the master iron regulator.Bioscience reports · 2015Review
- Erythropoietin's inhibiting impact on hepcidin expression occurs indirectly.American journal of physiology. Regulatory, integrative and comparative physiology · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Erythropoiesis-stimulating agents (ESA) are now central to the treatment of renal anemia and are associated with improved clinical outcomes. It is well known that erythropoietin (EPO) is a key regulator of erythropoiesis through its promotion of red blood cell production. In order to investigate the role of ESA on iron metabolism, we analyzed the regulation of the iron regulatory hormone hepcidin by ESA treatment in a bone marrow transplant model in mouse. After treating C57BL/6 mice with continuous erythropoietin receptor activator (C.E.R.A.), recombinant human epoetin-β (rhEPO), or recombinant human carbamylated epoetin-β (rhCEPO), we investigated serum hepcidin concentrations and parameters of erythropoiesis. Serum hepcidin concentrations after rhEPO treatment were analyzed in mice subjected to total body irradiation followed by bone marrow transplantation. C.E.R.A. administration caused long-term downregulation of serum hepcidin levels. Serum hepcidin levels in rhEPO-treated mice decreased significantly, whereas there was no change in rhCEPO-treated mice. The reduction in circulating hepcidin levels after rhEPO administration was not observed in irradiated mice. Finally, bone marrow transplantation recovered the response to rhEPO administration that downregulates hepcidin concentration in irradiated mice. These results indicate that ESA treatment downregulates serum hepcidin concentrations, mainly by indirect mechanisms affecting hematopoietic activity in bone marrow cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.